Rujianing (Lerociclib) – Breast Cancer | HongKong DengYue Medicine

Lerociclib Application Scope

It is an oral, selective CDK4/6 inhibitor approved for the treatment of HR+/HER2- advanced or metastatic breast cancer in adults. It can be combined with:

• Aromatase inhibitors as first-line endocrine therapy

• Fulvestrant for patients progressing after prior endocrine therapy

It is designed for continuous oral administration, providing sustained target inhibition with a favorable safety profile, including reduced risk of severe neutropenia and diarrhea compared to other CDK4/6 inhibitors.

Lerociclib Characteristics

• Ingredients: Lerociclib Hydrochloride (active ingredient)

• Properties:​ Oral film-coated tablet

• Packaging Specification:​ 50 mg × 42 tablets/box

• Storage:​ Store in a cool, dry place below 25°C, protect from light and moisture

• Expiry Date: As per manufacturer

• Executive Standard: ​NMPA-approved standard for oral oncology drugs

• Approval Number: NMPA Class 1 Innovative Drug (Approved: 2025/05/29)

• Date of Revision: 2025-05-29

• Manufacturer: Jiahe Biopharma (Cayman) Holdings Ltd.

Guidelines for the Use of Rujianing

• Dosage and Administration:

  • Recommended Dose: 50 mg orally, once daily (as per physician’s guidance)

  • Administration: Continuous oral dosing

  • Missed Dose:​ Take as soon as remembered; do not double-dose dose

• Adverse Reactions:

  • Common Adverse Reactions: Neutropenia, fatigue, nausea

  • Serious Adverse Reactions: Severe neutropenia, thrombocytopenia

    ​

• Contraindications:

  • Hypersensitivity to Lerociclib or excipients

  • Severe hepatic impairment

• Precautions:

  • Monitor blood counts regularly.

  • Adjust dose in case of hematologic toxicity.

  Lerociclib Interactions

• Concomitant strong CYP3A4 inhibitors or inducers may alter plasma levels.

• Avoid live vaccines during treatment.

• Use caution with other myelosuppressive agents.

Note:

• If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
•  This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.